Companies Dominating the Breast Recurrence Score Test Landscape
- Genomic Health, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Agendia, Inc.
- NanoString Technologies, Inc.
- Myriad Genetics, Inc.
- Thermo Fisher Scientific, Inc.
- Illumina, Inc.
- Roche Holdings AG
- Biotheranostics, Inc.
- Qiagen N.V.
- Veracyte, Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of breast recurrence score test is evaluated at USD 4.16 billion.
The breast recurrence score test market size was valued at USD 3.95 billion in 2024 and is set to exceed USD 8.74 billion by 2037, expanding at over 6.3% CAGR during the forecast period i.e., between 2025-2037. Increasing demand for healthcare sector will fuel the market growth.
Asia Pacific industry is poised to dominate majority revenue share of 38% by 2037, impelled by surge in shifting towards patient-centered care in the region.
The major players in the market are Genomic Health, Inc., Agendia, Inc., NanoString Technologies, Inc., Myriad Genetics, Inc., Thermo Fisher Scientific, Inc., Illumina, Inc., and others.
